Xueli Lv

949 total citations · 1 hit paper
18 papers, 769 citations indexed

About

Xueli Lv is a scholar working on Molecular Biology, Biomedical Engineering and Surgery. According to data from OpenAlex, Xueli Lv has authored 18 papers receiving a total of 769 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Biomedical Engineering and 4 papers in Surgery. Recurrent topics in Xueli Lv's work include Nanoplatforms for cancer theranostics (4 papers), Airway Management and Intubation Techniques (2 papers) and RNA Interference and Gene Delivery (2 papers). Xueli Lv is often cited by papers focused on Nanoplatforms for cancer theranostics (4 papers), Airway Management and Intubation Techniques (2 papers) and RNA Interference and Gene Delivery (2 papers). Xueli Lv collaborates with scholars based in China and United States. Xueli Lv's co-authors include Huanghao Yang, Shumeng Bai, Yu Shi, Chunhua Lü, Xueliang Zhang, Mengya Zhang, Xiaowei Huang, Jibin Song, Shaohua He and Jin Zhang and has published in prestigious journals such as Advanced Materials, Nano Letters and ACS Nano.

In The Last Decade

Xueli Lv

16 papers receiving 766 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A mussel-inspired supramolecular hydrogel with robust tissue anchor for rapid hemostasis of arterial and visceral bleedings

2021 228 citations Ziwen Qiao, Xueli Lv et al. Bioactive Materials profile →

Peers

Countries citing papers authored by Xueli Lv

Since Specialization

Citations

This map shows the geographic impact of Xueli Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xueli Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xueli Lv more than expected).

Fields of papers citing papers by Xueli Lv

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xueli Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xueli Lv. The network helps show where Xueli Lv may publish in the future.

Co-authorship network of co-authors of Xueli Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Xueli Lv. A scholar is included among the top collaborators of Xueli Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xueli Lv. Xueli Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Intracellular Delivery of Mitochondria-Targeting Cationic Polypeptides by pH-Responsive Nanoparticles to Induce Immunogenic Cell Death 2025 ·Biomacromolecules ·(unknown), Zhihui Guo, Xueli Lv, (unknown), (unknown), Wei Shen, Xuan Yi, Peng Zhang, Chunsheng Xiao, Xuesi Chen	0
2	Systematic review and meta-analysis of cardiovascular event incidence and risk factors in pediatric dialysis patients 2025 ·Medicine ·Xiaoying Zheng, (unknown), (unknown), Xueli Lv, Dongmei Wang	0
3	Tumor microenvironment-activated polypeptide nanoparticles for oncolytic immunotherapy 2024 ·Biomaterials ·(unknown), (unknown), Xueli Lv, (unknown), (unknown), Gao Li, (unknown), Chunsheng Xiao, Xuesi Chen	5
4	DNA-Free Guanosine-Based Polymer Nanoreactors with Multienzyme Activities for Ferroptosis–Apoptosis Combined Antitumor Therapy 2024 ·ACS Nano ·Xiaonong Zhang, Yingqi Zhang, Xueli Lv, Peng Zhang, Chunsheng Xiao, Xuesi Chen	14
5	Coacervation‐Driven Semipermeable Nanoreactors for Enzymatic Cascade‐Mediated Cancer Combination Therapy with Enhanced Efficacy 2024 ·Advanced Materials ·Min Lin, Xueli Lv, (unknown), (unknown), Helin Wang, (unknown), Jing Sun, Xuesi Chen	13
6	Polysulfonium: Unveiling a Bioactive Polymer to Induce Immunogenic Cell Death for Anticancer Therapy 2024 ·Nano Letters ·Xueli Lv, (unknown), Min Lin, Zhihui Guo, (unknown), (unknown), Chunsheng Xiao, Jing Sun, Xuesi Chen	7
7	Contrasting seasonal response of comammox Nitrospira and canonical ammonia oxidizers in two paddy soils 2022 ·Soil Biology and Biochemistry ·Shuling Wang, (unknown), Zhihui Wang, Xueli Lv, Alan L. Wright, Xianjun Jiang	12
8	Effects of Systemic Lidocaine on Postoperative Recovery Quality and Immune Function in Patients Undergoing Laparoscopic Radical Gastrectomy 2021 ·Drug Design Development and Therapy ·Xueli Lv, Xiaoxiao Li, (unknown), Tong Li, Yuping Yang, (unknown), Shuting Wang, Su Liu	14
9	A mussel-inspired supramolecular hydrogel with robust tissue anchor for rapid hemostasis of arterial and visceral bleedings breakdown → 2021 ·Bioactive Materials ·Ziwen Qiao, Xueli Lv, Shaohua He, Shumeng Bai, Xiaochen Liu, Linxi Hou, Jingjing He, Dongmei Tong, Renjie Ruan, Jin Zhang, Jianxun Ding, Huanghao Yang	228
10	CircGOT1 promotes cell proliferation, mobility, and glycolysis-mediated cisplatin resistance via inhibiting its host gene GOT1 in esophageal squamous cell cancer 2021 ·Cell Cycle ·(unknown), Zhiyuan Guo, Xueli Lv, (unknown)	21
11	The efficacy and safety of intrathecal dexmedetomidine for parturients undergoing cesarean section: a double-blind randomized controlled trial 2020 ·BMC Anesthesiology ·Xiaoxiao Li, Yumei Li, Xueli Lv, (unknown), Su Liu	12
12	<p>Application of Intravenous Lidocaine in Obese Patients Undergoing Painless Colonoscopy: A Prospective, Randomized, Double-Blind, Controlled Study</p> 2020 ·Drug Design Development and Therapy ·Xiaoxiao Li, Xueli Lv, (unknown), (unknown), Xinghe Wang, Tong Li, Lianyi Zhang, Su Liu	18
13	Incidence of postoperative sore throat after using a new technique of insertion of a second generation Laryngeal Mask Airway 2020 ·European Journal of Anaesthesiology ·Xiaoxiao Li, (unknown), (unknown), (unknown), Xueli Lv, (unknown), (unknown), Xinghe Wang, (unknown), Su Liu	7
14	Glycyrrhizin improved autophagy flux via HMGB1-dependent Akt/mTOR signaling pathway to prevent Doxorubicin-induced cardiotoxicity 2020 ·Toxicology ·Xueli Lv, (unknown), (unknown), Shi-Chang Zhang, Qing Zhang, Boxin Zhao, Guofeng Li	41
15	Bioinspired Mineral–Organic Bone Adhesives for Stable Fracture Fixation and Accelerated Bone Regeneration 2019 ·Advanced Functional Materials ·Shumeng Bai, Xueliang Zhang, Xueli Lv, Mengya Zhang, Xiaowei Huang, Yu Shi, Chunhua Lü, Jibin Song, Huanghao Yang	189
16	Formulation of injectable glycyrrhizic acid-hydroxycamptothecin micelles as new generation of DNA topoisomerase I inhibitor for enhanced antitumor activity 2019 ·International Journal of Pharmaceutics ·(unknown), (unknown), Xueli Lv, (unknown), (unknown), Boxin Zhao, Qing Zhang, Guofeng Li	32
17	Novobiocin, a Newly Found TRPV1 Inhibitor, Attenuates the Expression of TRPV1 in Rat Intestine and Intestinal Epithelial Cell Line IEC-6 2018 ·Frontiers in Pharmacology ·(unknown), Xueli Lv, Qing Cai, Yun Cai, Boxin Zhao, (unknown)	6
18	Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma 2014 ·Cell Death and Disease ·(unknown), Qinghua Wu, Z Liu, Xiaojun Luo, Yue Fan, Yicheng Liu, Yiyue Zhang, Shengni Hua, Qiangqiang Fu, Meng Zhao, (unknown), Weiyi Fang, Xueli Lv	150

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact